EMC China Lab

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices

Views :
Update time : 2025-03-01

With the implementation of ISO 10993-1:2018, most devices that have prolonged contact with the human body (>30 days) now require an evaluation of chronic toxicity and carcinogenicity as part of their biological risk assessment. In Table A.1 (iso 10993-1:2018), these biological endpoints are marked with an "E", indicating that they must be evaluated during risk assessment. This evaluation can be conducted using existing data, additional endpoint-specific tests, or a justified rationale explaining why additional data are unnecessary. The inclusion of these biological evaluation endpoints has also drawn regulatory attention, with review feedback requiring further refinement of chronic toxicity and carcinogenicity assessments based on Table A.1.

 

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices(图1)


Chronic Toxicity Test (Project Duration: ~8–14 months)

Chronic toxicity is a systemic toxicity study conducted by repeated or continuous exposure to the test sample throughout a significant portion of the animal's lifespan to observe any adverse effects. Animals should be continuously exposed for 6–12 months. When using rodents (rats, mice) for single-dose group studies, each group should include at least 30 animals (15 per sex). The evaluation of repeated exposure studies is based on body weight, clinical observations, hematology, clinical biochemistry, gross pathology, histopathology, and other test indicators.

 

Carcinogenicity Test (Project Duration: ~32–34 months)

The purpose of the carcinogenicity test is to assess tumor development in test animals during or after exposure to different doses of the test material through appropriate routes, covering major life stages of the animals.

 

- If an extract-based test is used, a standalone carcinogenicity study can be conducted according to OECD TG 451, or a combined chronic toxicity and carcinogenicity study can be conducted following OECD TG 453 to comprehensively evaluate both biological endpoints while considering the possibility of solid-state carcinogenicity.

- When evaluating the carcinogenicity of a medical device using a single animal species, the selection and justification should follow ISO 10993-2.

- For rodents, each group should include at least 50 animals per sex, with the study typically lasting 24 months to cover most of the animal’s lifespan.

 

Evaluation criteria include body weight, clinical observations, tumor formation and progression, hematology, gross pathology, histopathology, and other test indicators. Although transgenic animals can be used for carcinogenicity tests, their application in medical device evaluations has not yet been established.

 

Alternatives to Animal Testing for Chronic Toxicity and Carcinogenicity Evaluations

Both chronic toxicity and carcinogenicity studies involve long-term animal testing, posing significant financial and time challenges for product development. So, is animal testing always necessary for evaluating these biological endpoints?

 

According to iso 10993-18 (Material Chemical Characterization) and ISO 10993-17 (Toxicological Risk Assessment), toxicological evaluations based on material characterization can be used for assessing systemic toxicity endpoints, including:

 

- Systemic toxicity (acute, subacute, subchronic, and chronic toxicity)

- Genotoxicity

- Reproductive toxicity

- Carcinogenicity

 

Therefore, when determining whether to conduct chronic toxicity and carcinogenicity studies, it is essential to first consider the intended use and classification of the device to identify whether these biological endpoints require evaluation.

 

Manufacturers should leverage existing product information as much as possible, including raw materials, manufacturing processes, preclinical and clinical data (if available). When additional studies are necessary to support risk assessment, a tiered approach is recommended:

 

1. Prioritize chemical and physical characterization

2. Perform in vitro screening tests

3. Review characterization and in vitro test results before proceeding with animal testing

4. Justify the necessity of long-term animal studies

 

By following this approach, the biological risk assessment can be conducted in a scientifically rational and efficient manner.


Email:hello@jjrlab.com


Leave Your Message


Write your message here and send it to us


Related News
Read More >>
CPSC eFiling Process Guide for Amazon Shipments CPSC eFiling Process Guide for Amazon Shipments
06 .17.2026
JJR Lab provides CPSC testing for Amazon shipments under CPC and GCC standards, ensuring smooth eFil...
SAA approval testing services SAA approval testing services
06 .17.2026
JJR Lab provides FCC HAC testing for mobile phones under 47 CFR FCC and ANSI standards, supporting 1...
US FCC 100% Hearing Aid Compatibility (HAC) for Mo US FCC 100% Hearing Aid Compatibility (HAC) for Mo
06 .17.2026
JJR provides FCC HAC testing for mobile phones under 47 CFR FCC rules and ANSI standards, supporting...
Australia Food Contact Testing Australia Food Contact Testing
06 .17.2026
JJR provides Australia food contact testing under FSANZ-related standards, including AS 2070, EU 10/...
ISED RF Testing Services ISED RF Testing Services
06 .16.2026
JJR LAB provides ISED RF and SAR testing for Canada, using ICES-003, RSS series and FCC-aligned EMI ...
CEC Energy Efficiency Compliance Service CEC Energy Efficiency Compliance Service
06 .16.2026
JJR LAB provides CEC compliance testing under California Energy Commission rules using IEC 62087 and...
U.S. DOE Energy Efficiency Compliance Testing Serv U.S. DOE Energy Efficiency Compliance Testing Serv
06 .16.2026
U.S. DOE Energy Efficiency Compliance Testing by JJR Lab. We provide testing and certification suppo...
FDA Compliance Testing for Food Contact Products FDA Compliance Testing for Food Contact Products
06 .16.2026
JJR Lab provides FDA compliance testing for food contact products, covering FDA 21 CFR standards suc...

Leave Your Message